← Back to Search

Platelet-rich Plasma (PRP) for Arthroscopic Surgery

N/A
Waitlist Available
Led By David Kulber, MD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 time points (change from pre to post-op): pre-op, post op: month 1, month 3, month 6 and year 1; subjects will be followed for 12 months post arthroscopic debridement.
Awards & highlights

Study Summary

This trial will compare whether adding platelet-rich plasma to arthroscopic debridement helps heal TFCC tears better than just arthroscopic debridement.

Eligible Conditions
  • Arthroscopic Surgery
  • Triangular Fibrocartilage Complex Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 time points (change from pre to post-op): pre-op, post op: month 1, month 3, month 6 and year 1; subjects will be followed for 12 months post arthroscopic debridement.
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 time points (change from pre to post-op): pre-op, post op: month 1, month 3, month 6 and year 1; subjects will be followed for 12 months post arthroscopic debridement. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Modified Mayo Wrist Score - Functional Status Score
Modified Mayo Wrist Score - Grip Strength Score
Modified Mayo Wrist Score - Pain Score
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Platelet-rich Plasma (PRP) groupExperimental Treatment1 Intervention
Twenty-four (24) subjects undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will be treated intraoperatively with platelet-rich plasma (PRP) (24 subjects). Intervention: use of Cascade device; Autologous Fibrin & Platelet System; once processed, the platelet-rich plasma (PRP)is injected into the debrided wrist
Group II: Standard Treatment groupActive Control1 Intervention
Twenty-four (24) subjects undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will undergo treatment, as is standard of care, followed by no treatment with platelet-rich plasma (PRP)(24 subjects). Intervention: No platelet-rich plasma (PRP) injection into debrided wrist
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Platelet-rich Plasma (PRP)
2011
N/A
~120

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
500 Previous Clinical Trials
164,853 Total Patients Enrolled
David Kulber, MDPrincipal InvestigatorCedars-Sinai
2 Previous Clinical Trials
75 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears
David Kulber, MD 2019. "Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03805698.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top